UY39681A - Derivados de ciclobutilo 1,3–sustituidos y sus usos - Google Patents
Derivados de ciclobutilo 1,3–sustituidos y sus usosInfo
- Publication number
- UY39681A UY39681A UY0001039681A UY39681A UY39681A UY 39681 A UY39681 A UY 39681A UY 0001039681 A UY0001039681 A UY 0001039681A UY 39681 A UY39681 A UY 39681A UY 39681 A UY39681 A UY 39681A
- Authority
- UY
- Uruguay
- Prior art keywords
- substituted cyclobutyl
- treatment
- disorders
- diseases
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163166289P | 2021-03-26 | 2021-03-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY39681A true UY39681A (es) | 2022-10-31 |
Family
ID=80999265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001039681A UY39681A (es) | 2021-03-26 | 2022-03-22 | Derivados de ciclobutilo 1,3–sustituidos y sus usos |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11845730B2 (enExample) |
| EP (1) | EP4313951A1 (enExample) |
| JP (1) | JP7887908B2 (enExample) |
| KR (1) | KR20230162660A (enExample) |
| CN (1) | CN117062804A (enExample) |
| AR (1) | AR125196A1 (enExample) |
| AU (1) | AU2022244467A1 (enExample) |
| CA (1) | CA3214066A1 (enExample) |
| IL (1) | IL307189B1 (enExample) |
| MX (1) | MX2023011377A (enExample) |
| PY (1) | PY2221203A (enExample) |
| TW (1) | TWI924820B (enExample) |
| UY (1) | UY39681A (enExample) |
| WO (1) | WO2022201097A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR125196A1 (es) * | 2021-03-26 | 2023-06-21 | Novartis Ag | Derivados de ciclobutilo 1,3-sustituidos y sus usos |
| JP2025531367A (ja) * | 2022-09-21 | 2025-09-19 | ボシュ ＋ ロム アイルランド リミテッド | Ｔｒｐｖ１アンタゴニストの結晶多形形態およびその製剤 |
| US20240148709A1 (en) * | 2022-11-08 | 2024-05-09 | Aisa Pharma, Inc. | Methods of treating eye pain and eye disorders |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| US6933311B2 (en) | 2003-02-11 | 2005-08-23 | Abbott Laboratories | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
| US7514562B2 (en) | 2003-03-07 | 2009-04-07 | Glaxo Group Limited | Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain |
| GB0412769D0 (en) | 2004-06-08 | 2004-07-07 | Novartis Ag | Organic compounds |
| RU2451014C2 (ru) | 2005-07-22 | 2012-05-20 | Мотида Фармасьютикал Ко., Лтд. | Новое производное гетероциклиден ацетамида |
| KR20090031898A (ko) * | 2006-07-13 | 2009-03-30 | 교와 핫꼬 기린 가부시키가이샤 | 펜타디엔아미드 유도체 |
| CN101595094B (zh) | 2006-12-27 | 2013-02-20 | 塞诺菲-安万特股份有限公司 | 环烷基胺取代的异喹诺酮衍生物 |
| WO2012072512A1 (en) * | 2010-11-29 | 2012-06-07 | Glaxo Group Limited | N-cyclobutyl-imidazopyridine or -pyrazolopyridine carboxamides as trpv1 antagonists |
| DE102010052781A1 (de) * | 2010-11-30 | 2012-05-31 | Trw Automotive Gmbh | Befestigungsvorrichtung und Befestigungsbaugruppe zur Befestigung eines Gasgenerators und Fahrzeuginsassenrückhaltesystem |
| WO2012134943A1 (en) | 2011-03-25 | 2012-10-04 | Abbott Laboratories | Trpv1 antagonists |
| US8754101B2 (en) | 2011-04-11 | 2014-06-17 | Glaxo Group Limited | N-cyclobutyl-imidazopyridine-methylamine as TRPV1 antagonists |
| WO2017079162A1 (en) | 2015-11-02 | 2017-05-11 | Castar, Inc | Method of immersive rendering for wide field of view |
| US10269906B2 (en) * | 2016-11-30 | 2019-04-23 | Taiwan Semiconductor Manufacturing Co., Ltd. | Semiconductor device having two spacers |
| WO2018151678A1 (en) | 2017-02-15 | 2018-08-23 | Agency For Science, Technology And Research | Compounds for treatment of cancer and epigenetics |
| US11542248B2 (en) | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
| JP7594787B2 (ja) | 2018-12-07 | 2024-12-05 | ユニバーシティ オブ メリーランド、ボルチモア | 非ＡＴＰ／触媒部位ｐ３８マイトジェン活性化プロテインキナーゼ阻害剤 |
| AR125196A1 (es) * | 2021-03-26 | 2023-06-21 | Novartis Ag | Derivados de ciclobutilo 1,3-sustituidos y sus usos |
-
2022
- 2022-03-22 AR ARP220100676A patent/AR125196A1/es unknown
- 2022-03-22 UY UY0001039681A patent/UY39681A/es unknown
- 2022-03-23 PY PY202202221203A patent/PY2221203A/es unknown
- 2022-03-24 CN CN202280024266.2A patent/CN117062804A/zh active Pending
- 2022-03-24 WO PCT/IB2022/052720 patent/WO2022201097A1/en not_active Ceased
- 2022-03-24 KR KR1020237036535A patent/KR20230162660A/ko active Pending
- 2022-03-24 US US17/656,313 patent/US11845730B2/en active Active
- 2022-03-24 EP EP22714016.7A patent/EP4313951A1/en active Pending
- 2022-03-24 TW TW111111060A patent/TWI924820B/zh active
- 2022-03-24 AU AU2022244467A patent/AU2022244467A1/en active Pending
- 2022-03-24 CA CA3214066A patent/CA3214066A1/en active Pending
- 2022-03-24 JP JP2023558324A patent/JP7887908B2/ja active Active
- 2022-03-24 IL IL307189A patent/IL307189B1/en unknown
- 2022-03-24 MX MX2023011377A patent/MX2023011377A/es unknown
-
2023
- 2023-10-24 US US18/493,441 patent/US12435040B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3214066A1 (en) | 2022-09-29 |
| BR112023019496A2 (pt) | 2023-12-05 |
| AU2022244467A1 (en) | 2023-10-12 |
| JP7887908B2 (ja) | 2026-07-10 |
| KR20230162660A (ko) | 2023-11-28 |
| WO2022201097A1 (en) | 2022-09-29 |
| US20240308965A1 (en) | 2024-09-19 |
| IL307189A (en) | 2023-11-01 |
| EP4313951A1 (en) | 2024-02-07 |
| IL307189B1 (en) | 2026-08-01 |
| US12435040B2 (en) | 2025-10-07 |
| US11845730B2 (en) | 2023-12-19 |
| AR125196A1 (es) | 2023-06-21 |
| TW202304864A (zh) | 2023-02-01 |
| CN117062804A (zh) | 2023-11-14 |
| MX2023011377A (es) | 2023-10-06 |
| PY2221203A (es) | 2022-11-24 |
| US20220324811A1 (en) | 2022-10-13 |
| JP2024510778A (ja) | 2024-03-11 |
| TWI924820B (zh) | 2026-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2025002925A1 (es) | Compuestos derivados de pirido[4,3–d]pirimidina y uso para tratar cáncer. | |
| CR20230256A (es) | Compuestos farmacéuticos | |
| AR128931A1 (es) | Inhibidores del factor b del complemento y usos de los mismos | |
| ECSP21004787A (es) | Inhibidores de inflamasoma nlrp3 | |
| MA59373B1 (fr) | [1,3]diazino[5,4-d]pyrimidines en tant qu'inhibiteurs de her2 | |
| CO2022012884A2 (es) | Compuestos de amino pirimidina fusionados | |
| MX2023011377A (es) | Derivados de ciclobutilo 1,3-sustituidos y sus usos. | |
| GT200400116A (es) | Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades. | |
| ATE440834T1 (de) | Substituierte arylaminderivate und verwendungsverfahren | |
| DOP2010000064A (es) | 2-anilinopurin 8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos | |
| AR123685A1 (es) | Antagonistas del mrgx2 | |
| EP4663190A3 (en) | Muscarinic receptor agonists | |
| CR20210630A (es) | Inhibidores de monoacilglicerol lipasa (magl) heterocíclicos | |
| MX2023013683A (es) | Compuestos de isoxazolilo fusionados como inhibidores de lisina acetiltransferasa 6a (kat6a). | |
| AR133953A1 (es) | Inhibidores del factor b del complemento y usos de los mismos | |
| CL2021003455A1 (es) | Análogos de 3-(5-meti l-1 ,3-tiazol-2-1 l)-n--{( 1 r)-1-[2-(trifluoro-metil)pirimidin-5-il]etil}benzamida | |
| AR127470A1 (es) | Inhibidores de lrrk2 | |
| EP4635494A3 (en) | AMIDO HETERO-ROMATIC COMPOUNDS | |
| CL2025000120A1 (es) | Compuestos de piridinona sustituida como inhibidores de cbl-b. | |
| ECSP22040362A (es) | Derivados de 1,2,4oxadiazol como agonistas del receptor hepático x | |
| AR132880A1 (es) | Derivados de heteroaril como inhibidores de ddr | |
| DOP2019000299A (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
| JOP20250164A1 (ar) | مركبات تعديل مستقبلات الدوبامين d3/d2 | |
| CL2025001109A1 (es) | Compuestos derivados de pirazina-carboxamida. | |
| ZA202306305B (en) | Pharmaceutical compounds |